Erinlar 150 mg (Capsule)

Title

• Erinlar

Categories

• Medicine
• Cancer Treatment

Description

• Erinlar is a kinase inhibitor used for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive.

Dosage and Administration

• 450 mg orally once daily with food until disease progression or unacceptable toxicity

Indications

• Treatment of metastatic non-small cell lung cancer (NSCLC) with ALK-positive tumors

Pharmacology

• Targets ALK, IGF-1R, InsR, ROS1; Most active against ALK; Peak plasma levels at 4 to 6 hours; Absorption, Distribution, Elimination, Metabolism, Excretion details provided

Mode of Action

• Kinase inhibition including ALK, IGF-1R, InsR, ROS1

Interaction

• Effect of Other Drugs on Erinlar
• Effect of Erinlar on Other Drugs
• Strong CYP3A Inhibitors
• Strong CYP3A Inducers
• CYP3A Substrates
• CYP2C9 Substrates

Contraindications

• Known hypersensitivity to Ceritinib or any other components of this product

Side Effects

• Gastrointestinal Adverse Reactions
• Hepatotoxicity
• Interstitial Lung Disease/Pneumonitis
• QT Interval Prolongation
• Hyperglycemia
• Bradycardia
• Pancreatitis

Precautions and Warnings

• Gastrointestinal Adverse Reactions
• Hepatotoxicity
• Interstitial Lung Disease (ILD)/Pneumonitis
• QT Interval Prolongation
• Hyperglycemia
• Bradycardia
• Pancreatitis
• Embryo-Fetal Toxicity

Pregnancy and Lactation

• Can cause fetal harm; Advised not to breastfeed during treatment; Potential hazard to the fetus; No data regarding presence in human milk or effects on the breastfed infant or milk production

Use in Special Populations

• Females
• Males
• Pediatric Use
• Geriatric Use
• Hepatic Impairment

Storage Conditions

• Store below 30°C in a cool and dry place, away from sunlight; Keep out of reach of children

Pediatric Uses

• The safety and effectiveness of Erinlar in pediatric patients have not been established.

Drug-drug Interactions

• CYP3A4/P-gp inhibitors
• Strong CYP3A inducers
• CYP3A substrates
• CYP2C9 substrates

Pharmacokinetics

• Peak plasma levels, distribution to red blood cells, clearance, metabolism, and excretion provided

Special Populations

• Pregnancy
• Lactation
• Pediatric Use
• Geriatric Use
• Hepatic Impairment

Usability

• Oral administration
• Patient selection based on ALK positivity in tumor specimens
• Dose adjustment based on missed dose or vomiting

Technical Specifications

• Absolute bioavailability not determined
• 97% bound to human plasma proteins
• Volume of distribution of 4230 L

Design Elements

• Cool and dry storage conditions
• Sunlight protection
• Keep out of reach of children

Materials

• Ceritinib as the active kinase inhibitor

Functions

• Treatment of metastatic non-small cell lung cancer with ALK-positive tumors

Related Brands